Compare Neurocrine Biosciences Inc (NBIX) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Toronto-Dominion Bank — how do they compare? Neurocrine Biosciences Inc trades at $152.18 (market cap $16.46B), while Toronto-Dominion Bank trades at $121.35 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 12.2× Neurocrine Biosciences Inc's market cap, and Toronto-Dominion Bank pays a 2.63% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TD | |
|---|---|---|
Market Cap | $16.46B | $200.48B |
Sector | Health | Financials |
52-Week High | $185.50 | $124.80 |
52-Week Low | $123.10 | $72.85 |
Enterprise Value | $16.48B | — |
Dividend Yield | — | 2.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
